Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.05% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 8.48B.
Undervalued
The company’s latest PE is 9.54, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 148.94M shares, decreasing 5.51% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 63.32M shares of this stock.